PulseSight Therapeutics to Present Data on PST-611 at EVER Congress 2024

PARIS, Oct. 07, 2024 (GLOBE NEWSWIRE) — PulseSight Therapeutics SAS, an ophthalmology biotech company developing disruptive non-viral vectorized therapies with minimally-invasive delivery technology, is pleased to confirm that it will be presenting data on its lead program PST-611, expressing human … Read More 

SPRIM PRO Announces a Novel and Validated Approach for Monitoring Infant Growth from Home in Clinical Trials, Reducing Burdens on Caregivers and Clinical Sites

September 24, 2024, SPRIM PRO – SPRIM PRO, a CRO renowned for its innovative approach to clinical trials and healthcare, is excited to announce its accepted, peer reviewed publication in Frontiers in Pediatrics medical journal entitled, “Assessment of the reliability … Read More 

ObvioHealth announces strategic investment by Guardant Health to accelerate deployment of oncology clinical trials globally

July 25, 2024 – (PRNewswire) – ObvioHealth, a global digital clinical trials company, announces a new strategic investment by Guardant Health, Inc., a leading precision oncology company offering liquid and tissue biopsy tests across the cancer research and care continuum. … Read More 

Forbes Australia recognizes Prota Therapeutics for making waves in Australia’s startup scene at the moment

June 18, 2024 – (Forbes Australia) – Founder and CEO Mimi Tang has spent almost three decades working in allergy immunology. For much of that time, she was unsatisfied with the common approach – avoid the allergen and turn to … Read More 

ObvioHealth Strengthens Leadership Team with Key Industry Appointments

NEW YORK, Oct. 17, 2023 – ObvioHealth, a virtual research organization (VRO) delivering stronger clinical evidence through tech-enabled trials, announces the appointment of John Cassidy as its new Chief Financial Officer and Florence Mowlem as Vice President of Science. The two industry veterans will reinforce the … Read More 

Readout AI Secures Pre-Seed Funding to Decrease the Time from Clinical Trial Data to Clinical Trial Insight

LOS ANGELES, July 14, 2023 — Today, Readout AI is announcing it has raised its pre-seed funding. The round, led by Meridian Street Capital, with participation from Mucker Capital, Necessary Ventures, and angel investor Ryan Fukushima (COO of Tempus and CEO of Pathos), … Read More 

SPRIM Global Investments Pte. Ltd. completes equity investment in UK specialist clinical trial site, VCTC Ltd.

SINGAPORE, May 26, 2023 – SPRIM Global Investments (SPRIM), a leading health sciences investment firm, completed an equity investment in VCTC Limited, a UK-based specialist clinical trial site. SPRIM funding will enable VCTC to expedite growth through expansion of services and access to … Read More 

ObvioHealth Signs R&D Partnership with A*STAR to Identify and Develop Novel Digital Biomarkers

May 3, 2023 — NEW YORK — ObvioHealth, a pioneering virtual research organization (VRO) announces a partnership with A*STAR’s Singapore Institute for Clinical Sciences (SICS) to identify better and more sensitive ways to measure and capture health outcomes. A*STAR’s SICS aims to identify biomarkers … Read More 

ObvioHealth to Conduct a Pioneering Decentralized Clinical Trial on The Mi-Helper Device for Treatment of Migraine

NEW YORK, March 16, 2023 /PRNewswire/ — ObvioHealth and Mi-Helper, Inc. announce a partnership to conduct a decentralized clinical trial for a non-invasive neuromodulation device for the treatment of migraines. The randomized controlled trial will be fully remote, enabling data … Read More 

Treos Bio Announces First Patient Dosed in Phase 2 Trial of PolyPEPI1018 in Combination with Roche’s PD-L1-Inhibitor for the Treatment of Metastatic Colorectal Cancer

LONDON, June 27, 2022 (GLOBE NEWSWIRE) — Treos Bio Limited (“Treos”), a clinical stage biotechnology company using data science and proprietary biomarkers to develop precision peptide immunotherapies, today announced that the first patient has been dosed in the OBERTO 301 … Read More 

SPRIM Global Investments names Susan Dallabrida as Chief Executive Officer of SPRIM Consultancy

NEW YORK – February 8, 2022 – SPRIM Global Investments announces the promotion of Susan Dallabrida, PhD, to Chief Executive Officer of SPRIM Consultancy. In her nearly 2 years with SPRIM, Susan has brought both scientific and commercial leadership to … Read More 

Leveraging Next-Gen Tools in Rare Disease Research

By Susan Dallabrida, PhD The capture of high-quality, accurate and complete datasets in a clinical trial is always of utmost importance. But the stakes could not be higher when it comes to rare disease. It is estimated that there are … Read More 

Fibronostics Raises $8 Million in Series A Financing

Fibronostics, a global company providing non-invasive, algorithmic diagnostics for NASH patients, announced today that it has secured $8 million in series A funding. The financing round was led by AT Capital, a leading private investment firm in Asia and Elev8.vc, an early-stage deep-tech VC fund. … Read More 

Fibronostics Appoints Dr. Stephen A. Harrison to its Board of Advisors

Fibronostics, a global diagnostics company, providing non-invasive, algorithmic diagnostics to detect and manage metabolic diseases, announced today Stephen A. Harrison, MD has joined its board of advisors. … Read More 

The Critical Need for Virtual COVID-19 Clinical Trials and Patient Training

COVID-19 drug development has brought a unique set of clinical challenges, virtual patient training and decentralized trials can be part of the solution. … Read More 

ObvioHealth and Hôpital Paris Saint-Joseph Announce Partnership to Track COVID-19 in Oncology Patients

PARIS — June 18, 2020 – ObvioHealth, a full-service virtual research organization (VROTM), announces today a partnership with La Foundation Hôpital Paris Saint Joseph to monitor COVID-19 prevalence and symptoms among the oncology patients of the Groupe Hospitalier Paris Saint … Read More 

Travecta Therapeutics Announces it has Closed its Oversubscribed Series A Round at $27 Million

Travecta Therapeutics, announces today it has raised an additional $12 million in financing, closing its Series A round at a total of $27 million. … Read More 

SPRIM Partners with Health Catalyst to Analyze COVID-19 Impact on NASH and NAFLD

SPRIM and Health Catalyst partner to jumpstart understanding of COVID-19 impact on NASH and NAFLD population to advance clinical trials for liver disease. … Read More 

ObvioHealth Secures $17 Million in Latest Investment Round

ObvioHealth, a leading virtual health research organization or VRO, announced today it has raised $17 million in its latest round of financing. This round of financing comes on the heels of a global alliance with a strategic partner announced in March. … Read More 

ObvioHealth Launches Virtual COVID-19 Symptoms & Immune Response Registry

ObvioHealth, a digital research company, announces the launch of a registry to monitor COVID-19 prevalence, symptoms and immune response in the United States over the coming 12 months. … Read More 

Poster: Achieving Diversity in Clinical Trials

Learn how social media and digital clinical trials were used for recruiting participants in under-represented racial and ethnic groups. … Read More 

Digital vs. Traditional Clinical Trials: Examining the Differences

Digital clinical trials are conducted in a much different format than that of the traditional “brick and mortar” model. The following infographic will highlight some of the key differences between the two. … Read More 

How SPRIM’s Practice Areas & Sister Companies Work Together to Build the Future of Health

A breakdown of the four practices areas SPRIM utilizes to help its clients meet their commercial endpoints: strategy and innovation, regulatory and scientific affairs, research and clinical services and medical marketing and engagement. … Read More 

Recruiting a Diverse Subject Population

Woman taking blood pressure of a patient

SPRIM’s portfolio company, ObvioHealth, conducted a double-blind, randomized clinical trial to study the impact of rice vinegar on blood pressure and vascular reactivity. ObvioHealth focused on recruiting minorities, given that high blood pressure disproportionately impacts the black population in the U.S. … Read More 

Clinical Trial Recruitment: Old Habits Die Hard

Pedestrians in a crosswalk

Despite the emergence of the digital age of recruitment, the standard (aged) approaches to recruitment persist: media advertising (television, newspaper advertisements), physician referrals, press releases/public service announcements, posting fliers, physician referrals, random mailings, and cold calls are all still in play. … Read More 

Bring Your Own Device in Clinical Research: The Four C’s

“BYOD” or “bring your own device” is the future of clinical studies, and sponsors are embracing what will become the new standard. Subjects using their own devices to fill out diaries and input data is not only less expensive for … Read More 

Objective GI Funding Announcement

Objective GI, a gastrointestinal-focused clinical research company, announces a key investment by TKS 1, a joint venture between SPRIM and Tikehau Capital, enabling the company to grow its network of GI-specialty clinical research sites in the United States. … Read More 

Startups Aim to Fix ‘Broken’ Clinical Trials System

ObvioHealth, meanwhile, has developed an app that enables studies to be run using mobile devices. Data from smart devices such as a Bluetooth blood pressure monitor can integrate with the app, according to the company, which earlier this year raised … Read More 

ObvioHealth’s Milo Demonstrates How Digital Technology Improves Patient Experience, Compliance and Data Capture Using ClaimIt.

MILO & CLAIMIT View a short, imagined study where ObvioHealth’s Milo demonstrates how digital technology improves patient experience, compliance and data capture using ClaimIt. Follow our fictional subject, Milo, as he uses his mobile phone to participate in a clinical … Read More 

Solving the Blood‑Brain Barrier Challenge

The blood brain barrier (BBB) is a system of blood vessels that protects the brain from toxins and chemical fluctuations. While it is necessary to help keep the brain healthy, it also poses a problem in delivering medications that could … Read More 

Fighting Antibiotic Associated Diarrhea

NEW YORK (Reuters Health) – A commercially available formula of Lactobacillus acidophilus and L. casei prevents Clostridium difficile infection and diarrhea during antibiotic treatment, according to a single-center study from China. Although meta-analyses indicate that probiotics decrease antibiotic-associated diarrhea, most … Read More 

3 Ways Mobile Clinical Trials Help Clinical Researchers Improve Diversity

Lack of diversity within the clinical trial industry poses a grave problem. We cannot assume medicines work similarly across ethnicities. While attracting and retaining minority groups to participate in clinical trials has become a primary focus in the industry, many … Read More 

Scientific Study Shows Milk with Only the A2 Beta Casein Protein Type Reduced Acute Gastrointestinal Symptoms in Milk Sensitive Participants

BUSINESSWIRE, 12 February 2018 NEW YORK–(BUSINESS WIRE)–A double-blind, randomized, cross-over study, published in the UK-based, peer-reviewed Nutrition Journal, reported that consumption of milk containing only A2 beta casein protein type (sold in the US as a2 Milk®) reduced acute gastrointestinal … Read More 

Tackling the blood-brain barrier: Duke-NUS discovery leads to startup Travecta

HONG KONG – Travecta Therapeutics Pte Ltd. is the latest startup to join Singapore’s biotech block. The newly formed drug discovery company is based on intellectual property derived from discoveries made at Duke-NUS Medical School (Duke-NUS). Travecta is based on … Read More 

Vanteres: New Study Reveals the Importance of Active-DHA in the Developing Brain

PHILADELPHIA–(BUSINESS WIRE)–Vanteres, an innovative biotech company leveraging its biomedical research expertise to develop actively transported lysophospholipids, announces new evidence that demonstrates the critical role of LPC-DHA in normal fetal and infant brain development. … Read More 

Forbes: ObvioHealth To Transform Clinical Studies

ObvioHealth, supported by SPRIM, releases a Mobile App that is positioned to transform clinical studies globally. … Read More 

ObvioHealth Announces Mobile Application

ORLANDO, Fla.–(BUSINESS WIRE)–ObvioHealth, a global medical technology company, announces the launch of its mobile application for site-less clinical studies— the ObvioHealth app. The app removes barriers currently troubling the clinical research industry by improving convenience for study subjects, enhancing compliance, … Read More 

ObvioHealth Raises $3 Million in Series A Funding

ObvioHealth, a Singapore and Orlando-based company offering mobile and “site-less” clinical trials, said on Friday it has raised US$3 million in Series A funding. The company is focused on making clinical trials faster and more cost-effective by digitizing the entire process … Read More